Alpha Family Trust Buys 4,005 Shares of Johnson & Johnson (NYSE:JNJ)

Alpha Family Trust boosted its stake in Johnson & Johnson (NYSE:JNJ) by 180.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,230 shares of the company’s stock after acquiring an additional 4,005 shares during the period. Alpha Family Trust’s holdings in Johnson & Johnson were worth $986,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in JNJ. Christopher J. Hasenberg Inc purchased a new position in shares of Johnson & Johnson in the first quarter worth about $31,000. Keener Financial Planning LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $40,000. WFA Asset Management Corp grew its stake in Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $44,000. Finally, Disciplined Equity Management Inc. purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $45,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on JNJ shares. TD Securities reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, July 1st. The Goldman Sachs Group dropped their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Thursday. Finally, Bank of America dropped their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $175.00.

Johnson & Johnson Trading Down 0.7 %

Johnson & Johnson stock traded down $1.13 during mid-day trading on Friday, reaching $154.29. 3,642,554 shares of the company traded hands, compared to its average volume of 7,308,396. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The firm’s 50 day moving average price is $148.26 and its 200 day moving average price is $153.40. The firm has a market capitalization of $371.33 billion, a price-to-earnings ratio of 9.64, a P/E/G ratio of 2.76 and a beta of 0.52. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.79%. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.80 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.21%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.